PCI Biotech awarded NOK 12.5 million from The Research Council of Norway to further development of PCI for use in vaccination NewsadminJanuary 30, 2014
Successful completion of the first group in the intra-tumour light dose escalation part of the ENHANCE study NewsadminJanuary 24, 2014
Results from preclinical in vivo vaccination studies showing that the PCI technology can significantly improve therapeutically relevant immune responses accepted for publication NewsadminDecember 12, 2013
Update on clinical studies – both clinical studies now open for patient inclusion. NewsadminDecember 12, 2013
ENHANCE Study - Optimization of intra-tumour illumination and changes in patient population NewsadminMarch 5, 2013
PCI Biotech – Winner of both DnB NOR’s Innovation prize 2011 and the People’s award NewsadminSeptember 7, 2011
Successful completion of the third dose group in the Amphinex study. Continued good tolerability and strong tumour response is reported, with an apparent high treatment specificity for cancer cells. NewsadminMarch 16, 2010
PCI Biotech reports successful completion of second dose group in a Phase I/II Amphinex® trial. Strong anti-tumour response observed in all patients NewsadminJanuary 19, 2010
Initiated pre-clinical trials for the use of PCI in the treatment of Bladder Cancer NewsadminDecember 3, 2009
Successful completion of the first dose group in the Phase I/II study of Amphinex® in cancer patients NewsadminOctober 19, 2009
First cancer patient included in PCI Biotech's Phase I/II trial of Amphinex® NewsadminAugust 24, 2009
